Low-dose IL-2 study after heart bypass surgery
Treatments studied
Part of Heart & circulation clinical trials.
This study tests whether a low dose of a natural immune-boosting protein (IL-2) given after heart bypass surgery can help reduce heart damage. The treatment aims to activate special immune cells that protect heart tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must be scheduled for or have recently had coronary artery bypass grafting (CABG) surgery—a type of heart surgery to improve blood flow
- You cannot have certain heart rhythm problems or severe blockages that make you unstable
- You cannot have autoimmune disease or be taking regular immune-suppressing medications
- You cannot have active infection, HIV, hepatitis, or active cancer requiring treatment
- If you can become pregnant, you cannot be pregnant or breastfeeding, and must use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking a low dose of colchicine, an anti-inflammatory medicine, after heart bypass surgery can help keep the new blood vessels open and working well. It may help reduce the chance of the bypass grafts failing.
This trial tests whether a supplement called alpha ketoglutarate (AKG) can help older adults recover better after heart bypass surgery. If you are 50 or older and scheduled for elective bypass surgery, you may be able to join.
This study is checking on people who finished a previous trial (IVORY) that tested a low-dose treatment called IL-2 for reducing inflammation after a heart attack. It will see how they are doing over time and if the treatment helped their heart health.
This study tests a new treatment using donor stem cells injected into the heart during scheduled bypass surgery. The goal is to see if these cells help improve heart function in people with heart failure due to blocked arteries and a weak heart pump.
This trial tests whether a low dose of a drug called IL-2 can help control both lupus and a common virus called cytomegalovirus (CMV). It may reduce lupus symptoms while helping your body fight off the virus.
This trial tests a low dose of IL-2 to reduce inflammation and help control Crohn’s disease symptoms. It’s for people whose Crohn’s disease hasn’t responded to at least one standard treatment or who need steroids to stay under control.
Hear when a new Coronary artery disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.